Singapore markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
186.94-3.17 (-1.67%)
At close: 04:00PM EST
187.76 +0.82 (+0.44%)
Pre-market: 04:59AM EST
Full screen
Trade prices are not sourced from all markets
Previous close190.11
Bid186.50 x 1000
Ask189.40 x 800
Day's range186.42 - 192.61
52-week range176.36 - 242.99
Avg. volume1,591,877
Market cap47.53B
Beta (5Y monthly)0.60
PE ratio (TTM)22.42
EPS (TTM)8.34
Earnings date31 Jan 2022 - 04 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est251.30
  • Motley Fool

    Will This Beaten-Down Stock Bounce Back? 3 Things to Know

    Vertex Pharmaceuticals (NASDAQ: VRTX) has given more than one investor a headache over the past year. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments. Considering the time Vertex shares have spent in the doldrums, you may be getting a little impatient.

  • Zacks

    CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation

    The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.

  • Motley Fool

    Better Buy: Vertex Pharmaceuticals vs. CRISPR

    Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) each have their own strengths. Vertex has developed a blockbuster portfolio of cystic fibrosis (CF) treatments. CRISPR is working on gene-editing treatments for a variety of serious diseases.